A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

Inclusion Criteria:

• Voluntarily sign and date the study consent form(s) which have been approved by anInstitutional Review Board (IRB). Written consent must be obtained prior to theinitiation of any study procedures.
• Male between 18 and 80 years of age, inclusive, with documented onset of hypogonadismprior to age 65.
• Serum total testosterone < 300 ng/dL based on 2 consecutive blood samples obtained nogreater than 1-4 weeks apart between 6 and 10 AM following an appropriate washout ofcurrent androgen replacement therapy if not testosterone naive. Historical values fromthe past 6 months may be used.
• Testosterone Therapy naive, OR off any testosterone therapy for at least 4 months ORagree to a 4-month washout of current testosterone therapy prior to entry at Visit 1.
• Average office blood pressure measurement <140 millimetre of mercury (mmHg) SBP -AND- <90 mmHg DBP.
• If the participant is on an antihypertensive regimen, he has been on it for at least 4weeks.
• Judged to be in good general health as determined by the principal investigator basedupon the results of a medical history, physical examination, vital signs, laboratoryprofile and a 12-lead electrocardiogram (ECG).

Exclusion Criteria:

• History of significant sensitivity or allergy to androgens, castor oil or productexcipients.
• Clinically significant findings in the pre-study examinations including abnormalbreast examination requiring follow-up, an abnormal ECG.
• Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) orInternational Prostate Symptom Score (I-PSS) score > 19 points.
• Body mass index (BMI) ≥ 35 kg/m^2.
• Clinically significant abnormal laboratory value, in the opinion of the investigator,in serum chemistry, hematology, or urinalysis including but not limited to:
• Prostate specific antigen (PSA) > 4 ng/mL
• Hematocrit < 35% or > 50%
• Baseline hemoglobin > 16 g/dL
• Hemoglobin A1C (HbA1C) > 9.0%
• Estimated glomerular filtration rate (eGFR) <45
• History of seizures or convulsions, including febrile, alcohol or drug withdrawalseizures.
• History of any clinically significant illness, infection, or surgical procedure within 4 weeks prior to study drug administration except for diabetes, or renal disease.
• History of stroke or myocardial infarction within the past 5 years.
• History of, or current or suspected, prostate or breast cancer.
• History of diagnosed, severe, untreated, obstructive sleep apnea.
• History of abuse of alcohol or any drug substance in the opinion of the investigatorwithin the previous 2 years.
• Currently using tobacco, e-cigarettes or other nicotine containing products.
• History of nasal disorders such as nasal surgery; nasal trauma resulting in nasalfracture within the previous 6 months or nasal fracture that caused a deviatedanterior nasal septum; or sinus surgery or sinus disease.
• Receipt of any investigational product within 4 weeks of study start.
• Inability to understand and provide written informed consent for the study.
• Considered by the investigator or the sponsor-designated physician, for any reason, asan unsuitable candidate to receive Natesto.
• Participants working night-shifts.
• Participants performing strenuous manual labor while wearing the ABPM monitor.
• Participants with chronic atrial fibrillation (interferes with the ability to obtainprecise ambulatory recordings).